title: Targeting CDK9: a promising therapeutic opportunity in prostate cancer.
abstract: Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment. Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression. In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen. CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and anti-apoptotic proteins, improving the chances of positive outcomes, especially in patients with the advanced disease. This review focuses on biological functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.
authors: Muhammed H
authors: MH
authors: Rahaman
authors: Malika
authors: M
authors: Kumarasiri
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors: Laychiluh B
authors: LB
authors: Mekonnen
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors: Mingfeng
authors: M
authors: Yu
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors: Sarah
authors: S
authors: Diab
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors: Hugo
authors: H
authors: Albrecht
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors: Robert W
authors: RW
authors: Milne
authors: Centre for Drug Discovery and DevelopmentSansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia shudong.wang@unisa.edu.au.
authors: Shudong
authors: S
authors: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D042863:Cyclin-Dependent Kinase 9 / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C467969:CDK9 protein, human; D042863:Cyclin-Dependent Kinase 9
keywords: CDK9; RNAPII transcription; anti-apoptotic proteins; apoptosis; prostate cancer; therapeutics